FIP1L1::PDGFRA in myeloid/lymphoid neoplasms with eosinophilia and TK fusions

1 EU-approved indication in myeloid/lymphoid neoplasms with eosinophilia and TK fusions needs a FIP1L1::PDGFRA result: imatinib (advanced).

Line of therapy

Approved indications, Myeloid/lymphoid neoplasms with eosinophilia and TK fusions
DrugBiomarker requirementRegimenSettingConditions
FIP1L1::PDGFRA fusion1
Imatinib
Glivec
FIP1L1-PDGFRalpha rearrangement
Monotherapy
Any line
advanced
None

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Imatinib (Glivec)
    adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.